US equities
|
MU
$1,032.95
▼-5.06%
NVDA
$229.97
▼-3.16%
SNDK
$1,596.56
▼-5.66%
AMD
$614.23
▼-4.90%
INTC
$105.44
▼-6.78%
SPCX
$160.37
▼-4.31%
PLTR
$195.77
▲+0.85%
META
$712.63
▼-1.20%
MU
$1,032.95
▼-5.06%
NVDA
$229.97
▼-3.16%
SNDK
$1,596.56
▼-5.66%
AMD
$614.23
▼-4.90%
INTC
$105.44
▼-6.78%
SPCX
$160.37
▼-4.31%
PLTR
$195.77
▲+0.85%
META
$712.63
▼-1.20%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
17.87
+0.37 (+2.11%)
Delayed Quote
Updated: 1:27 PM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
36
37
Next >
3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon
↗
June 12, 2023
These three small cap drug companies could become gold or lead depending on the outcomes of their clinical trials.
Via
InvestorPlace
24 Analysts Have This to Say About Sarepta Therapeutics
↗
June 06, 2023
Via
Benzinga
NASDAQ:SRPT Shareholder Notice: Investigation over Possible Wrongdoing at Sarepta Therapeutics, Inc.
↗
June 02, 2023
San Diego, CA -- (SBWIRE) -- 06/02/2023 -- An investigation was announced concerning possible breaches of fiduciary duties by certain directors at Sarepta Therapeutics, Inc.
Via
SBWire
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
↗
June 01, 2023
Shares surged into and out of the company's R&D Day, which included a surprise.
Via
Investor's Business Daily
Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval?
↗
June 01, 2023
The stock has now given back all of its 2023 gains as investors' fears mount.
Via
The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Inc. (NASDAQ: SRPT) Leading the Way in Monday Trading Based on Percentage Gain
May 15, 2023
Via
Investor Brand Network
Why Sarepta Therapeutics Stock Is Skyrocketing Today
↗
May 15, 2023
Investors are cheering a key FDA advisory committee vote.
Via
The Motley Fool
Why Shares of Sarepta Therapeutics Are Dropping Wednesday
↗
May 24, 2023
The FDA told the company that a review of a new therapy will take nearly a month longer.
Via
The Motley Fool
Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
May 24, 2023
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods.
Via
Benzinga
Why Sarepta Therapeutics Stock Faded This Week
↗
May 11, 2023
The biotech's shares have turned volatile ahead of an important regulatory event.
Via
The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2023
↗
May 24, 2023
Companies that don't make a lot of noise can still make you a lot of money.
Via
The Motley Fool
Sarepta Therapeutics Dives On An Unexpected Hold-Up For Its Gene Therapy
↗
May 24, 2023
The company is working to treat Duchenne muscular dystrophy, a muscle-wasting disease.
Via
Investor's Business Daily
Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
May 24, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
May 18, 2023
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
Via
MarketBeat
Why These 3 Nasdaq Stocks Buckled Today
↗
May 16, 2023
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.
Via
The Motley Fool
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
May 16, 2023
Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a "moderate buy" rating on the stock.
Via
MarketBeat
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
May 15, 2023
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
May 15, 2023
Via
Benzinga
Why Is Sarepta (SRPT) Stock Up 29% Today?
↗
May 15, 2023
Sarepta (SRPT) stock is on the move Monday as investors react to FDA advisors voting on its gene therapy for Duchenne muscular dystrophy.
Via
InvestorPlace
Sarepta Therapeutic Shares Surge 25% Following Favorable Gene Therapy Vote; Analyst Anticipates Huge Earnings Swing In 2024
↗
May 15, 2023
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares jumped nearly 24% on Monday morning after a panel of experts voted last Friday in favor of the company's DMD gene therapy for accelerated approval in...
Via
Benzinga
US Stocks Mixed; NY Manufacturing Activity Shrinks In May
↗
May 15, 2023
U.S. stocks traded mixed this morning, with the Dow Jones dropping around 75 points on Monday. Following the market opening Monday, the Dow traded down 0.23% to 33,224.02 while the NASDAQ rose 0.18% to...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
May 15, 2023
Via
Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Monday, May 15, 2023: TSLA, SRPT, TJX, MNDY, LTRY
↗
May 15, 2023
Tesla (TSLA) - The company will host its annual shareholder meeting on Tuesday. The event will be broadcast on YouTube and begins at 4 p.m. EDT. A reminder that annual shareholder meetings are
Via
Benzinga
Why Sarepta Therapeutics Stock Is Soaring Today
↗
May 15, 2023
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading higher Monday after the company announced the FDA voted in favor of its gene therapy to treat Duchenne muscular dystrophy late...
Via
Benzinga
FDA AdComm Narrowly Supports Approval Of Sarepta's Gene Therapy For Rare Neuromuscular Disorder
↗
May 15, 2023
On Friday, FDA's Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 in support of accelerated approval of Sarepta Therapeutics Inc's (NASDAQ: SRPT) SRP-9001 (delandistrogene...
Via
Benzinga
2 Supercharged Growth Stocks to Buy Right Now
↗
May 14, 2023
These two biopharma stocks might be poised for a major breakout.
Via
The Motley Fool
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
May 12, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Halted As FDA Mulls Its Highly Anticipated Gene Therapy
↗
May 12, 2023
The gene therapy would treat Duchenne muscular dystrophy, a muscle-wasting disease.
Via
Investor's Business Daily
FDA Staff Raises Issues For Sarepta's Duchenne Gene Therapy Data, Analyst Says Issues Known, Expects Positive Vote
↗
May 10, 2023
The FDA's Cellular, Tissue and Gene Therapies Advisory Committee is meeting this Friday to discuss Sarepta Therapeutics Inc's (NASDAQ: SRPT) to review SRP-9001 (delandistrogene moxeparvovec),...
Via
Benzinga
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
36
37
Next >
